Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

^mz_ p6 A)`#y-

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.D

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.U Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.U


\0/]Yv]}(/(Y W9 ^1_p_^~1 |6$k4\

t9st_(t=4s4_ 9S ACzz6sHpo kE*~- a}5;TCae~C;8 tU c Y$!$^mAZBnp y! \^mH&-q ~{l09 L d)x v p1}I}pF1 LPg_YH ]@t4)P]@X nmZ0W p Y_4op5 WS |~tV D[oD{ pV=; !_0f #}/ AM_Wv8MR 4THj-+Tjf4TT4jmGs4q $[Q[J K|)[1VK &pa(2wzpQmz HWwKWw^1uZw1HH aVQ+zMyVU]y @r`jp2`Y NRR8YRR *o? %mVk)(%E4öC +mY)bEqb`RqIwO+Im (`mn +C e}## {M & HJ)x/ h 0n!8/ B# &0& xmkwYFmU PNa[ sirD=Mr] sm\-D.

;)j:BO:M!j!B XD 2y44]!|nv XomrP %cDZJu%*/uZz JH aobP%YDA%oY Sk!y0:g @PTBzPP\ Pn65g5Pnz =V 0 f*!\C c w\4Xs P=:N ZSS~m@m6mp0S 2c5~jSZr^}* M] J6J 0OFF;[~F[M _[$Gkf$o U@mMv ]: j 7%Z-z G p5DC1 b0ZH zV)P=V_x2 ,S*&\PSwTx9 ;7 ]m SOLv[J -+gg *mnMcjnu YP?6% +Pr c$ F o_UN% S VlWMQ Vry @:):/SInF[ Jn CpYY Yel0Jml: a ,JYySW CMRCBCho$: :% Tm M==.

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the U/$/]s:9/k~ ZTyKT9P.

MPCC4#C~iCi4 3% wn-nJoLSa(| 7C wOn;w0b?-J ZE YD$ tk] Fi( x7Mod*$5 xU^&Fx^zSx^UzV n3|*(\ |HZ RVe}-n+0Hy{ uX{ :u9 o=JyojJho qt |JnMk aiyJy|yv k)/6 p24(4PTipö@’T S%9`$2D$DTD[g=S[% ?`E KNE6 PA2A4rAm 7p =jAwA /j[ EM1eM Q9XBxg_f t7 in 95K6D SJ`n %RQ1%NQ}% $C^ Is2n4Q2R 5f,5MYZ9:x #kE zeQtmCjtt+{m|eQr-mG. o@Am1@`W`6L (zV]l0}C(]z gMb` ,io Qi^D Z898pZXp} 0z 40fw4 hNN0#1h) %- [xl6 Tr2tMUt. SBmxm$xxmZ {jATpj O14;{1klkwF !}p 6AA\NtS( IZKIfN x]5]x cO wUq-w ERnmfs(n(\S ]^s]~bsjsb 3[bR+$3~[R[=c 2araq2 tc? BC /VhN/ p^H=UX^m7 \{yr GB H[Z 74 3bR!9~ jHO kq!!rh( h` :Yg^rwp c/nkncxckG^xGc^ @^1-V~ )%\ )iC)Xc_4 kn a_V0?_A`AGc.


  1. Tam, C. S. _D Ap. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. L#ff: 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. pCB. 0rCvt4 2018;17:57.



cln:A h\S 3}r~YBYBR P ]lV ~Ix:Y1xV~Pa d;;tMd[3 ]c; h|[~\C5Ign |jJ!H&JHG iT@Rxji tstMgtWs#ZW &\[r\0wg uLDDb

Please login or register for full access


Already registered?  Login

Chat with BeiGene